December 2, 2009 3:19 PM
- Text
Stem Cells Repair Heart Attack Damage
- Adele's Grammy Comeback After Vocal Cord Surgery
- Treating Sleep Apnea in Kids Improves Behavior, Quality of Life
- Chemo May Not Harm Unborn Baby
- C-Sections Not Always Best for Small Babies
- CDC: Doctors Increasingly Prescribe Exercise
- Osteoporosis Medication Linked to Unusual Thigh Fractures
- More from WebMD »
generic heart attack clock blood artery cells health stopwatch stop watch (CBS/iStockphoto)
(WebMD)
Can stem cells safely repair heart attack damage? Yes, a clinical trial suggests.
Bone marrow stem cells are supposed to home in on damaged parts of the heart. Once there, they send out signals that help the body repair the injury. There's also evidence, from animal studies, that the stem cells themselves engraft to the heart and help repopulate dead cells with new, living cells.
Now there's evidence from actual patients who suffered heart attacks. It comes from a study led by cardiologist Joshua M. Hare, director of the stem cell institute at the University of Miami Miller School of Medicine, and colleagues at nine other medical centers.
"Stem cell-treated patients had ... significant improvements in heart, lung, and global function," Hare said in a news release. "Echocardiography showed improved heart function, particularly in those patients with large amounts of cardiac damage."
It's not the first time heart attack patients have been treated with stem cells. But previous studies used bone marrow cells extracted from the patient and then injected directly into the heart.
Hare's team used an "off-the-shelf" stem cell product -- Prochymal -- containing stem cells harvested from a single healthy donor and grown to large numbers in laboratories. Prochymal is given by intravenous infusion. It's made by Osiris Therapeutics Inc., which sponsored the study, and which currently seeks FDA approval of the product as a treatment for graft-versus-host disease in transplant recipients.
"Many have argued that it's premature to test stem cells in patients," Hare said. "This trial ... lays the foundation for a brand new cell-based therapy for the human heart."
The Hare study enrolled 53 heart attack patients treated within 10 days of their first heart attack. None of the patients required bypass. A fourth of the patients got infusions of an inactive placebo; the others got various doses of the Prochymal cells.
The main goal of the study was to see if Prochymal was safe. It had been feared that the cells might cause growth of unwanted tissue in the arteries or the lungs. This did not happen. Patients receiving the stem cells had fewer adverse events than those who received placebo.
The secondary goal of the study was to gather some evidence that the treatment actually helped. There was such evidence -- particularly in the patients with the largest infarcts (patches of heart tissue killed during a heart attack).
Why? Emergency signals sent out by wounded heart tissue attract help from stem cells. It's probable that the stronger signal from the more damaged hearts attracted more of the stem cells to the site of injury, suggest Cleveland Clinic researchers Marc S. Penn, MD, PhD, and colleagues in an editorial accompanying the Hare report in the Dec. 8 issue of the Journal of the American College of Cardiology.
Warning that the Hare study is only a first step, Penn and colleagues call the findings "important."
"Many questions remain, but there is excitement in what the future holds with regard to advances in this field," they write.
A phase 2 clinical trial, also sponsored by Osiris, is enrolling heart attack patients.
By Daniel J. DeNoon
Reviewed by Louise Chang
©2005-2008 WebMD, LLC. All rights reserved
Bone marrow stem cells are supposed to home in on damaged parts of the heart. Once there, they send out signals that help the body repair the injury. There's also evidence, from animal studies, that the stem cells themselves engraft to the heart and help repopulate dead cells with new, living cells.
Now there's evidence from actual patients who suffered heart attacks. It comes from a study led by cardiologist Joshua M. Hare, director of the stem cell institute at the University of Miami Miller School of Medicine, and colleagues at nine other medical centers.
"Stem cell-treated patients had ... significant improvements in heart, lung, and global function," Hare said in a news release. "Echocardiography showed improved heart function, particularly in those patients with large amounts of cardiac damage."
It's not the first time heart attack patients have been treated with stem cells. But previous studies used bone marrow cells extracted from the patient and then injected directly into the heart.
Hare's team used an "off-the-shelf" stem cell product -- Prochymal -- containing stem cells harvested from a single healthy donor and grown to large numbers in laboratories. Prochymal is given by intravenous infusion. It's made by Osiris Therapeutics Inc., which sponsored the study, and which currently seeks FDA approval of the product as a treatment for graft-versus-host disease in transplant recipients.
"Many have argued that it's premature to test stem cells in patients," Hare said. "This trial ... lays the foundation for a brand new cell-based therapy for the human heart."
The Hare study enrolled 53 heart attack patients treated within 10 days of their first heart attack. None of the patients required bypass. A fourth of the patients got infusions of an inactive placebo; the others got various doses of the Prochymal cells.
The main goal of the study was to see if Prochymal was safe. It had been feared that the cells might cause growth of unwanted tissue in the arteries or the lungs. This did not happen. Patients receiving the stem cells had fewer adverse events than those who received placebo.
The secondary goal of the study was to gather some evidence that the treatment actually helped. There was such evidence -- particularly in the patients with the largest infarcts (patches of heart tissue killed during a heart attack).
Why? Emergency signals sent out by wounded heart tissue attract help from stem cells. It's probable that the stronger signal from the more damaged hearts attracted more of the stem cells to the site of injury, suggest Cleveland Clinic researchers Marc S. Penn, MD, PhD, and colleagues in an editorial accompanying the Hare report in the Dec. 8 issue of the Journal of the American College of Cardiology.
Warning that the Hare study is only a first step, Penn and colleagues call the findings "important."
"Many questions remain, but there is excitement in what the future holds with regard to advances in this field," they write.
A phase 2 clinical trial, also sponsored by Osiris, is enrolling heart attack patients.
By Daniel J. DeNoon
Reviewed by Louise Chang
©2005-2008 WebMD, LLC. All rights reserved
Popular Now in Health
- Cancer drug reverses Alzheimer's in mice: Study
- Norovirus outbreak hits Rider University in N.J
- Marijuana-smoking motorists twice as likely to crash
- Electric shocks to brain may boost memory: Study
- America's pets also have an obesity epidemic
- 4.5 million Americans over 50 have artificial knees
- Skin cancer self-exam: What to look for (PHOTOS)
- Caffeine inhalers - the next club drug?
- Measles patient at Super Bowl prompts health alert
- America's sodium problem: Not from salty snacks?
- Chinese mom gives birth to 15-pound baby
- Things You Didn't Know About Your Penis
- PICTURES: 15 Shocking Sexual Fetishes
- Let's Move! campaign turns 2 today: Is it working?
- John Dye Dies: What Killed "Angel" Star?
- Woman spotlights uterus didelphys on talk show
- Christina Hendricks: Too Big for Hollywood?
Latest CBS News Headlines
on Facebook
on CBS News
- Rap mogul arrested on Vegas traffic, drug charges
- McCreery, Gilbert, Hayes make ACM new artist cut
- Clemons' nephew to play sax on Springsteen tour
- Ranchera music star Fernandez announces retirement
on Facebook
- Adele sings a cappella for Anderson Cooper
- Occupy protestors kicked out of CPAC
- CPAC: Will Sarah Palin spring a surprise?
- Beyonce and Jay-Z post first photos of Blue Ivy Carter
on CBS News






